SG Americas Securities’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $283K | Sell |
1,416
-9,401
| -87% | -$1.86M | ﹤0.01% | 2486 |
|
|
2025
Q4 | $2.04M | Sell |
10,817
-905
| -8% | -$174K | ﹤0.01% | 1515 |
|
|
2025
Q3 | $2.08M | Buy |
11,722
+8,637
| +280% | +$1.28M | 0.01% | 927 |
|
|
2025
Q2 | $351K | Sell |
3,085
-3,723
| -55% | -$398K | ﹤0.01% | 1897 |
|
|
2025
Q1 | $716K | Buy |
6,808
+5,201
| +324% | +$588K | ﹤0.01% | 1473 |
|
|
2024
Q4 | $172K | Buy |
+1,607
| New | +$182K | ﹤0.01% | 2287 |
|
|
2024
Q3 | – | Sell |
-6,624
| Closed | -$558K | – | 3520 |
|
|
2024
Q2 | $558K | Sell |
6,624
-4,437
| -40% | -$353K | ﹤0.01% | 1625 |
|
|
2024
Q1 | $809K | Buy |
+11,061
| New | +$815K | ﹤0.01% | 1220 |
|
|
2023
Q4 | – | Sell |
-14,690
| Closed | -$880K | – | 3286 |
|
|
2023
Q3 | $880K | Buy |
14,690
+6,215
| +73% | +$409K | 0.01% | 1378 |
|
|
2023
Q2 | $611K | Sell |
8,475
-15,308
| -64% | -$1.15M | ﹤0.01% | 1312 |
|
|
2023
Q1 | $1.75M | Sell |
23,783
-14,055
| -37% | -$999K | 0.02% | 747 |
|
|
2022
Q4 | $2.53M | Buy |
+37,838
| New | +$2.46M | 0.03% | 472 |
|
|
2022
Q3 | – | Sell |
-12,862
| Closed | -$716K | – | 3389 |
|
|
2022
Q2 | $716K | Buy |
12,862
+3,727
| +41% | +$211K | 0.01% | 1628 |
|
|
2022
Q1 | $641K | Sell |
9,135
-4,500
| -33% | -$326K | ﹤0.01% | 1732 |
|
|
2021
Q4 | $1.31M | Buy |
13,635
+9,621
| +240% | +$889K | 0.01% | 1436 |
|
|
2021
Q3 | $349K | Sell |
4,014
-6,755
| -63% | -$522K | ﹤0.01% | 2802 |
|
|
2021
Q2 | $881K | Buy |
10,769
+3,006
| +39% | +$250K | ﹤0.01% | 1644 |
|
|
2021
Q1 | $738K | Sell |
7,763
-12,850
| -62% | -$1.21M | ﹤0.01% | 1744 |
|
|
2020
Q4 | $1.28M | Buy |
20,613
+7,492
| +57% | +$427K | 0.01% | 1395 |
|
|
2020
Q3 | $780K | Sell |
13,121
-4,821
| -27% | -$329K | 0.01% | 1340 |
|
|
2020
Q2 | $1.25M | Buy |
17,942
+7,303
| +69% | +$463K | 0.01% | 1191 |
|
|
2020
Q1 | $483K | Sell |
10,639
-6,797
| -39% | -$385K | ﹤0.01% | 1875 |
|
|
2019
Q4 | $1.13M | Buy |
17,436
+15,118
| +652% | +$1.01M | 0.01% | 1183 |
|
|
2019
Q3 | $144K | Sell |
2,318
-2,505
| -52% | -$157K | ﹤0.01% | 2532 |
|
|
2019
Q2 | $343K | Sell |
4,823
-5,250
| -52% | -$387K | ﹤0.01% | 2117 |
|
|
2019
Q1 | $790K | Sell |
10,073
-13,401
| -57% | -$1.02M | 0.01% | 1468 |
|
|
2018
Q4 | $1.99M | Buy |
23,474
+15,885
| +209% | +$1.69M | 0.02% | 884 |
|
|
2018
Q3 | $1.3M | Sell |
7,589
-8,948
| -54% | -$1.35M | 0.01% | 1498 |
|
|
2018
Q2 | $2.14M | Buy |
16,537
+14,418
| +680% | +$1.61M | 0.02% | 899 |
|
|
2018
Q1 | $218K | Buy |
2,119
+423
| +25% | +$41.8K | ﹤0.01% | 2378 |
|
|
2017
Q4 | $145K | Sell |
1,696
-5,364
| -76% | -$465K | ﹤0.01% | 2649 |
|
|
2017
Q3 | $600K | Buy |
7,060
+3,440
| +95% | +$272K | 0.01% | 1693 |
|
|
2017
Q2 | $274K | Sell |
3,620
-1,732
| -32% | -$121K | ﹤0.01% | 2213 |
|
|
2017
Q1 | $353K | Sell |
5,352
-9,517
| -64% | -$626K | ﹤0.01% | 2077 |
|
|
2016
Q4 | $943K | Buy |
14,869
+10,813
| +267% | +$682K | 0.01% | 1334 |
|
|
2016
Q3 | $258K | Buy |
+4,056
| New | +$298K | ﹤0.01% | 2272 |
|
|
2016
Q2 | – | Sell |
-2,092
| Closed | -$140K | – | 2826 |
|
|
2016
Q1 | $140K | Sell |
2,092
-401
| -16% | -$24.4K | ﹤0.01% | 2417 |
|
|
2015
Q4 | $169K | Sell |
2,493
-1,973
| -44% | -$122K | ﹤0.01% | 2186 |
|
|
2015
Q3 | $239K | Buy |
+4,466
| New | +$271K | ﹤0.01% | 1337 |
|
|
2015
Q2 | – | Sell |
-7,452
| Closed | -$358K | – | 2732 |
|
|
2015
Q1 | $358K | Sell |
7,452
-3,335
| -31% | -$128K | ﹤0.01% | 1595 |
|
|
2014
Q4 | $358K | Buy |
+10,787
| New | +$351K | ﹤0.01% | 1904 |
|
|
2014
Q3 | – | Sell |
-6,601
| Closed | -$257K | – | 2752 |
|
|
2014
Q2 | $257K | Buy |
+6,601
| New | +$268K | ﹤0.01% | 1913 |
|
|
2013
Q4 | – | Sell |
-4,803
| Closed | -$130K | – | 2841 |
|
|
2013
Q3 | $130K | Sell |
4,803
-1,708
| -26% | -$48.1K | ﹤0.01% | 2489 |
|
|
2013
Q2 | $152K | Buy |
+6,511
| New | +$117K | ﹤0.01% | 1875 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
SG Americas Securities's LGND Position: Q1 2026 in Review
SG Americas Securities reduced its Ligand Pharmaceuticals (LGND) stake by 87% in Q1 2026, selling an estimated $1.86M and leaving 1,416 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #2486.
SG Americas Securities first reported a position in LGND in Q2 2013 and has held it in 44 quarters since. The position peaked at $2.53M in Q4 2022. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- SG Americas Securities held 1,416 shares of Ligand Pharmaceuticals worth $283K as of Q1 2026.
- SG Americas Securities sold 9,401 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.86M.
- Ligand Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2486 holding.
- SG Americas Securities first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- SG Americas Securities's Ligand Pharmaceuticals position peaked at $2.53M in Q4 2022.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.